IDSA and HIVMA Position on the Criminalization of HIV, Sexually Transmitted Infections and Other Communicable Diseases | March 2015
Criminalization is not an effective strategy for reducing transmission of infectious diseases. IDSA and HIVMA urge state policy makers to promote public health by revising statutes that criminalize transmission of diseases, such as HIV infection, viral hepatitis and other communicable diseases.
Policy Statement on Syringe Access and Paraphernalia Laws | April 2014
Because transmission occurs through the sharing or re‐use of infected paraphernalia, access to uninfected injection equipment is a key part of infection prevention programs. Currently, Congress prohibits local health authorities from using federal funds for syringe exchange programs (SEPs).
The Role of Advanced Practice Registered Nurses and Physician Assistants in HIV Care Policy Statement | March 2014
HIVMA supports policy changes at the state level to allow APRNs and PAs to practice to the full extent of their training and expertise as members of HIV care teams and with established consultative relationships with HIV physicians.
Strategies for Health Insurers to Optimize Coverage for People with HIV | February 2014
HIVMA and AAHIVM recommendations for public and private insurers to support quality, cost-effective HIV Care.
Fair Antiretroviral Drug Pricing and Robust Coverage for Antiretrovirals: Critical Factors in Ending the HIV Pandemic | November 2012
A Joint Statement of the HIV Medicine Association (HIVMA) and the American Academy of HIV Medicine (AAHIVM).
Recommendations for the U.S. Response to Domestic and Global AIDS I July 2012
HIVMA responds to the results of the updated HPTN 052 study making policy recommendations.The findings from the study provide urgency to the quest to expand access to HIV care and treatment.
Solutions Needed to Address HIV Public Health Crisis in the US | January 2012
HIVMA calls on policymakers, industry partners, philanthropists, advocates, providers, and HIV professional organizations to collaborate to identify solutions to address the HIV public health crisis in the U.S.
HIVMA, Ryan White Policy Paper Identifies Key Components of Effective Care | October 2011
HIVMA and the Ryan White Medical Providers Coalition (RWMPC) developed a paper describing the ideal HIV care model and calling for innovative financing and continued public health funding to support this care and expand it.
Policy Statement on HIV Infected Organ Transplantation | September 2011
A change in policy is necessary to support medical progress and allow for research to fully evaluate HIV-infected organ donation to HIV‐infected patients.
Implications of HPTN 052 for the US Response to Domestic and Global AIDS | September 2011
HIVMA responds to the results of the HPTN 052 study making policy recommendations on the finding that early ART can prevent transmission between discordant couples and, at the same time, reduce disease progression in the infected partner.
HIV Policy: The Path Forward | April 2009
A joint position paper of HIVMA and the American College of Physicians (ACP). Since the last joint statement, many new developments call for the need to reexamine and update our policies relating to HIV infection.
Screening for HIV in Health Care Settings | January 2009
The American College of Physicians (ACP) developed this guidance statement to present the available evidence on screening for HIV in health care settings.
Preventing HIV and other Sexually Transmitted Infections: A Call for Science-Based Government Policies | April 2005
The HIV Medicine Association (HIVMA) and the Infectious Diseases Society of America (IDSA) are strongly committed to public health interventions that decrease the transmission of all infectious diseases. We believe strongly that the federal government must play a leading role in protecting our nation’s health by reducing the spread of STIs.
Policy Statement on Donor Screening Guidelines for Blood Donation | September 2004
HIVMA strongly supports the development of public policies based on science. It is for this reason that we believe the criteria used by the Food and Drug Administration (FDA) to exclude potential blood donors should be revised to reflect the reliability of current blood testing technology and scientific knowledge regarding HIV transmission.